Persistent Müllerian duct syndrome

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD medical weight loss NYC and sleep center NYC

Persistent Müllerian duct syndrome
Synonyms	PMDS
Pronounce	N/A
Specialty	N/A
Symptoms	Presence of Müllerian duct structures in a genetically male individual
Complications	Infertility, cryptorchidism, inguinal hernia
Onset	Congenital
Duration	Lifelong
Types	N/A
Causes	Mutations in the AMH or AMHR2 genes
Risks	Family history of the condition
Diagnosis	Genetic testing, imaging studies
Differential diagnosis	Androgen insensitivity syndrome, 5-alpha-reductase deficiency
Prevention	N/A
Treatment	Surgical removal of Müllerian structures, management of cryptorchidism
Medication	N/A
Prognosis	Generally good with treatment
Frequency	Rare
Deaths	N/A

Persistent Müllerian duct syndrome (PMDS) is a rare form of intersex condition in which individuals with a typically male karyotype (46,XY) and normal male external genitalia also have internal female reproductive structures, such as a uterus and fallopian tubes. This condition is caused by a failure in the regression of the Müllerian ducts during fetal development.

Pathophysiology

In typical male fetal development, the Müllerian ducts regress due to the secretion of Anti-Müllerian hormone (AMH) by the Sertoli cells of the testes. In PMDS, this process is disrupted, leading to the persistence of these ducts. The disruption can be due to mutations in the AMH gene or the AMH receptor gene, resulting in either a lack of AMH production or a failure of the body to respond to AMH.

Clinical Presentation

Individuals with PMDS usually present with normal male external genitalia and undescended testes (cryptorchidism). The presence of a uterus and fallopian tubes is often discovered incidentally during surgery for cryptorchidism or inguinal hernia repair. In some cases, the condition may be associated with infertility.

Diagnosis

Diagnosis of PMDS is typically made through a combination of clinical examination, imaging studies such as ultrasound or MRI, and genetic testing to identify mutations in the AMH or AMH receptor genes. Hormonal assays may also be conducted to assess levels of AMH and other relevant hormones.

Treatment

The primary treatment for PMDS involves surgical management of cryptorchidism to reduce the risk of testicular cancer and to potentially improve fertility. The removal of the persistent Müllerian structures is generally not necessary unless they cause symptoms or complications.

Prognosis

The prognosis for individuals with PMDS is generally good, especially if cryptorchidism is managed appropriately. However, there may be an increased risk of infertility and testicular cancer, necessitating regular follow-up and monitoring.

See also

• Intersex
• Cryptorchidism
• Anti-Müllerian hormone
• Testicular cancer
• Karyotype

See Also

• Disorders of sex development
• Genetic disorders

References

   This article is a medical stub. You can help WikiMD by expanding it!